secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0001193125-24-193923
Event type: debt
Sentiment:  negative
Materiality: 0.70
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica amends credit deal with OrbiMed; revenue test delayed, exit fee hiked, going concern waived
--------------------------------------------------------------------------------

- Revenue test under Credit Agreement now begins December 31, 2024, instead of earlier date.
- Lenders waived going concern qualification requirement for Q2 and Q3 2024 financial statements.
- Exit Fee on Initial Loans increased from 5.00% to 7.50%.
- YCANTH net revenue must meet specified thresholds to avoid principal payments under amended terms.
- Fifth Amendment modifies July 2023 Credit Agreement; other terms unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312524193923/0001193125-24-193923-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312524193923/d856804d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-193923

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer